William Blair Has Bearish Estimate for TARS Q2 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – William Blair reduced their Q2 2025 earnings estimates for shares of Tarsus Pharmaceuticals in a research note issued on Monday, July 14th. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn ($0.48) per share for the quarter, down from their prior forecast of ($0.43). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ FY2025 earnings at ($1.43) EPS.

A number of other research firms also recently commented on TARS. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. HC Wainwright upgraded shares of Tarsus Pharmaceuticals to a “buy” rating and set a $72.00 price objective on the stock in a research report on Tuesday, May 27th. Guggenheim increased their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. The Goldman Sachs Group boosted their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a “neutral” rating in a report on Monday, May 5th. Finally, Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a report on Monday, June 2nd. They issued an “outperform” rating and a $75.00 price target for the company. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $66.67.

Tarsus Pharmaceuticals Stock Up 2.4%

Shares of NASDAQ TARS opened at $41.55 on Wednesday. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -15.22 and a beta of 0.80. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.54 and a current ratio of 5.57. The stock’s 50-day simple moving average is $42.00 and its 200-day simple moving average is $46.79.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 39.72% and a negative net margin of 44.91%.

Institutional Trading of Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Toronto Dominion Bank acquired a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $105,714,000. Driehaus Capital Management LLC bought a new stake in shares of Tarsus Pharmaceuticals during the first quarter worth approximately $36,876,000. Lord Abbett & CO. LLC lifted its stake in shares of Tarsus Pharmaceuticals by 115.2% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock valued at $70,873,000 after purchasing an additional 685,111 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in Tarsus Pharmaceuticals in the first quarter valued at about $26,199,000. Finally, Millennium Management LLC boosted its stake in Tarsus Pharmaceuticals by 189.4% during the 4th quarter. Millennium Management LLC now owns 644,010 shares of the company’s stock worth $35,659,000 after acquiring an additional 421,495 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.